Antiviral Drugs - ASEAN

ASEAN

The Antiviral Drugs market in ASEAN is expected to experience significant growth in the coming years.
According to projections, the revenue in this market is projected to reach US$0.50bn by 2024.
Furthermore, it is anticipated that there will be an annual growth rate of 2.29% between 2024 and 2029, resulting in a market volume of US$0.56bn by the end of 2029.
When comparing the global market, it is noteworthy that United States is expected to generate the highest revenue in the Antiviral Drugs market, amounting to US$30,640.00m in 2024.
This demonstrates the dominance of the United States in this particular market.
The ASEAN region is experiencing a growing demand for antiviral drugs due to the increasing prevalence of viral diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral Drugs market in ASEAN is experiencing robust growth due to various factors.

Customer preferences: Customers in the ASEAN region are becoming increasingly aware of the importance of antiviral drugs in treating various viral infections. The growing prevalence of viral infections such as HIV, hepatitis, and influenza is driving demand for antiviral drugs in the region. Moreover, the COVID-19 pandemic has further boosted the demand for antiviral drugs in the region.

Trends in the market: Several trends are shaping the Antiviral Drugs market in the ASEAN region. Firstly, there is a growing trend towards the development of new antiviral drugs that are more effective and have fewer side effects. Secondly, there is an increasing trend towards the use of combination therapies that involve the use of two or more antiviral drugs to treat viral infections. Thirdly, there is a trend towards the use of generic antiviral drugs, which are more affordable than branded drugs.

Local special circumstances: The Antiviral Drugs market in the ASEAN region is characterized by several unique factors. Firstly, there is a high prevalence of viral infections in the region, which is driving demand for antiviral drugs. Secondly, there is a growing trend towards the use of traditional medicine in the region, which is driving demand for herbal antiviral drugs. Thirdly, there is a strong regulatory environment in the region, which is ensuring that only safe and effective antiviral drugs are available in the market.

Underlying macroeconomic factors: Several macroeconomic factors are driving the growth of the Antiviral Drugs market in the ASEAN region. Firstly, there is a growing middle class in the region, which is increasing the demand for healthcare products and services. Secondly, there is a growing awareness of the importance of healthcare in the region, which is driving demand for healthcare products and services. Thirdly, there is a growing trend towards medical tourism in the region, which is driving demand for antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.